HRP20040898A2 - 4-(n-phenylamino)-quinazolines/quinolines as tyrosine kinase inhibitors - Google Patents

4-(n-phenylamino)-quinazolines/quinolines as tyrosine kinase inhibitors Download PDF

Info

Publication number
HRP20040898A2
HRP20040898A2 HR20040898A HRP20040898A HRP20040898A2 HR P20040898 A2 HRP20040898 A2 HR P20040898A2 HR 20040898 A HR20040898 A HR 20040898A HR P20040898 A HRP20040898 A HR P20040898A HR P20040898 A2 HRP20040898 A2 HR P20040898A2
Authority
HR
Croatia
Prior art keywords
group
alkyl
amino
morpholin
oxo
Prior art date
Application number
HR20040898A
Other languages
English (en)
Croatian (hr)
Inventor
Himmelsbach Frank
Jung Birgit
Solca Flavio
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10214412A external-priority patent/DE10214412A1/de
Priority claimed from DE2002131711 external-priority patent/DE10231711A1/de
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Publication of HRP20040898A2 publication Critical patent/HRP20040898A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
HR20040898A 2002-03-30 2003-03-25 4-(n-phenylamino)-quinazolines/quinolines as tyrosine kinase inhibitors HRP20040898A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10214412A DE10214412A1 (de) 2002-03-30 2002-03-30 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE2002131711 DE10231711A1 (de) 2002-07-13 2002-07-13 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PCT/EP2003/003062 WO2003082290A1 (de) 2002-03-30 2003-03-25 4- ( n-phenylamino ) -chinazoline/chinoline als tyrosinkinaseinhibitoren

Publications (1)

Publication Number Publication Date
HRP20040898A2 true HRP20040898A2 (en) 2005-10-31

Family

ID=28676040

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040898A HRP20040898A2 (en) 2002-03-30 2003-03-25 4-(n-phenylamino)-quinazolines/quinolines as tyrosine kinase inhibitors

Country Status (23)

Country Link
EP (1) EP1492536B1 (pl)
JP (1) JP4776882B2 (pl)
KR (1) KR101064530B1 (pl)
CN (1) CN1642552B (pl)
AR (1) AR039187A1 (pl)
AT (1) ATE557008T1 (pl)
AU (1) AU2003226705B2 (pl)
BR (1) BR0308902A (pl)
CA (1) CA2476008C (pl)
EA (2) EA200701302A1 (pl)
HR (1) HRP20040898A2 (pl)
IL (1) IL164167A0 (pl)
ME (1) MEP47208A (pl)
MX (1) MXPA04009536A (pl)
MY (1) MY127771A (pl)
NO (1) NO329271B1 (pl)
NZ (1) NZ536114A (pl)
PE (1) PE20040169A1 (pl)
PL (1) PL371188A1 (pl)
RS (1) RS85404A (pl)
TW (2) TW201024269A (pl)
UY (1) UY27737A1 (pl)
WO (1) WO2003082290A1 (pl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1044769B (zh) 1999-06-21 2005-02-25 贝林格尔英格海姆法玛两合公司 雙環雜環化合物，含有該化合物的藥物組合物，該化合物的用途及其製備方法
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7576074B2 (en) * 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
BRPI0410720A (pt) * 2003-05-27 2006-06-20 Pfizer Prod Inc quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
DE10334226A1 (de) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
UY28441A1 (es) * 2003-07-29 2005-02-28 Astrazeneca Ab Derivados de quinazolina
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
EP1664028A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives as tyrosine kinase inhibitors
ATE395346T1 (de) * 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
ES2279441T3 (es) * 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10345875A1 (de) * 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung
DE10350717A1 (de) * 2003-10-30 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
MXPA06007018A (es) * 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de 3-ciano-quinolino con actividad anti-proliferativa.
MXPA06007017A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
DE602005010824D1 (de) 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
ATE501148T1 (de) 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1845992A1 (de) * 2005-02-04 2007-10-24 Boehringer Ingelheim International GmbH Verwendung von tyrosinkinase-inhibitoren zur behandlung der chronischen rhinosinusitis
WO2006081741A1 (en) * 2005-02-05 2006-08-10 Piaoyang Sun Quinazoline compounds or their medical salts and preparation and medical usage thereof
KR20070107151A (ko) * 2005-02-26 2007-11-06 아스트라제네카 아베 티로신 키나제 억제제로서의 퀴나졸린 유도체
CA2619037A1 (en) * 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof
ATE488513T1 (de) 2005-09-20 2010-12-15 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
JP2009518450A (ja) * 2005-12-12 2009-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式複素環化合物、その化合物を含む薬剤、その使用及び製造方法
US20090306105A1 (en) * 2006-03-09 2009-12-10 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them
JP2009542778A (ja) 2006-07-13 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｔｋｉキナゾリン誘導体
AU2007296746B2 (en) * 2006-09-11 2012-07-05 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033747A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
AU2007299080B2 (en) 2006-09-18 2013-04-18 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
EP1956010A1 (de) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel,deren Verwendung und Verfahren zu ihrer Herstellung
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
US8497369B2 (en) * 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
JP5739802B2 (ja) * 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
US8263768B2 (en) * 2008-08-08 2012-09-11 Boehringer Ingelheim International Gmbh Process for the stereoselective preparation of bicyclic heterocycles
EP2313398A1 (de) * 2008-08-08 2011-04-27 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP2313397B1 (de) * 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CN101659658B (zh) * 2008-08-29 2014-04-02 北大方正集团有限公司 氰基取代的喹啉衍生物
CN101659657B (zh) * 2008-08-29 2014-05-14 北大方正集团有限公司 氰基取代的喹啉衍生物及其制备方法和用途
US8629153B2 (en) * 2008-09-03 2014-01-14 Boehringer Ingelheim International Gmbh Use of quinazoline derivatives for the treatment of viral diseases
PT2451445T (pt) 2009-07-06 2019-07-10 Boehringer Ingelheim Int Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
WO2011035540A1 (zh) 2009-09-28 2011-03-31 齐鲁制药有限公司 作为酪氨酸激酶抑制剂的4-（取代苯胺基）喹唑啉衍生物
EP2414338A1 (de) * 2010-02-15 2012-02-08 Boehringer Ingelheim International GmbH Salze und hydrate des 4 -[(3-chlor-4-fluor-phenyl)amino]-6-(cis-4-{n-[(morph-1-olin-4-yl)carbonyl]-n-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-chinazolins, deren verwendung als arzneimittel und deren herstellung
CN102452988B (zh) * 2010-10-27 2016-01-27 中国科学院化学研究所 一种喹唑啉衍生物及其制备方法
AP3531A (en) 2011-02-01 2016-01-13 Boehringer Ingelheim Int 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140128318A (ko) 2012-02-09 2014-11-05 베링거 인겔하임 인터내셔날 게엠베하 1,4-보호된 9-하이드록시-5-옥소-1,4-디아자-스피로 [5.5] 운데칸의 입체선택적 합성 방법
EP2752413B1 (en) 2012-03-26 2016-03-23 Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences Quinazoline derivative and application thereof
WO2014012859A1 (en) 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
KR20140096571A (ko) 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
EP2964638B1 (en) * 2013-03-06 2017-08-09 Astrazeneca AB Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
EP3962908A4 (en) * 2019-04-25 2022-10-26 Board of Regents, The University of Texas System HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
EP4055014B1 (en) 2019-11-06 2025-04-30 Yuhan Corporation PYRROLIDINE AND PIPERIDINE COMPOUNDS
TW202208337A (zh) * 2020-05-04 2022-03-01 美商佛拉斯托醫療公司 Ｅｎｐｐ１之亞胺基硫烷酮抑制劑
IL310870A (en) * 2021-08-24 2024-04-01 Arthrosi Therapeutics Inc Quinazoline compounds for treatment of disease
WO2025152954A1 (zh) * 2024-01-15 2025-07-24 上海脉博实业有限公司 苯并嘧啶类化合物、其制备方法、药物组合物及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
DE10042059A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
BR0308902A (pt) 2005-01-04
AR039187A1 (es) 2005-02-09
PE20040169A1 (es) 2004-05-24
EA200701302A1 (ru) 2007-12-28
RS85404A (sr) 2007-02-05
CN1642552A (zh) 2005-07-20
KR101064530B1 (ko) 2011-09-14
TWI331604B (en) 2010-10-11
EA009300B1 (ru) 2007-12-28
NO329271B1 (no) 2010-09-20
CN1642552B (zh) 2010-05-12
EP1492536B1 (de) 2012-05-09
CA2476008C (en) 2011-12-13
UY27737A1 (es) 2003-10-31
WO2003082290A1 (de) 2003-10-09
MXPA04009536A (es) 2005-01-25
CA2476008A1 (en) 2003-10-09
JP4776882B2 (ja) 2011-09-21
PL371188A1 (pl) 2005-06-13
EP1492536A1 (de) 2005-01-05
JP2005529090A (ja) 2005-09-29
TW200406211A (en) 2004-05-01
NZ536114A (en) 2007-11-30
EA200401191A1 (ru) 2005-04-28
ATE557008T1 (de) 2012-05-15
TW201024269A (en) 2010-07-01
HK1079095A1 (zh) 2006-03-31
MY127771A (en) 2006-12-29
KR20040094898A (ko) 2004-11-10
MEP47208A (en) 2011-02-10
IL164167A0 (en) 2005-12-18
AU2003226705A1 (en) 2003-10-13
NO20043997L (no) 2004-10-27
AU2003226705B2 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
HRP20040898A2 (en) 4-(n-phenylamino)-quinazolines/quinolines as tyrosine kinase inhibitors
US7119084B2 (en) Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP3754617B2 (ja) 二環式複素環化合物、その化合物を含む医薬組成物、及び製法
JP4834282B2 (ja) 二環式複素環、それを含む医薬組成物、その使用及びその製造方法
US20020082270A1 (en) Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US20110136806A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
DE10326186A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CN101648947A (zh) 作为酪氨酸激酶抑制剂的4-(n-苯氨基)-喹唑啉/喹啉
US20070135463A1 (en) Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same
CA2540501C (en) Quinoline derivatives and quinazoline derivatives, medicaments containing said compounds, use thereof, and method for the production thereof
JP2007507445A6 (ja) キノリン及びキナゾリン誘導体、これを含む薬物、その使用及びその調製方法
HK1079095B (en) 4-(n-phenylamino)-quinazolines/quinolines as tyrosine kinase inhibitors

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20120228

Year of fee payment: 10

OBST Application withdrawn